Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer

This study has been completed.
Sponsor:
Collaborators:
Northwest Biotherapeutics
University of California, San Francisco
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00683241
First received: May 19, 2008
Last updated: February 25, 2013
Last verified: February 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2009
  Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)